| Primary |
| Bipolar Disorder |
38.5% |
| Bipolar I Disorder |
10.0% |
| Product Used For Unknown Indication |
9.0% |
| Depression |
7.2% |
| Drug Use For Unknown Indication |
5.1% |
| Mania |
4.5% |
| Schizoaffective Disorder |
3.8% |
| Hypertension |
3.5% |
| Drug Exposure During Pregnancy |
2.6% |
| Major Depression |
2.3% |
| Schizophrenia |
1.9% |
| Drug Toxicity |
1.6% |
| Psychotic Disorder |
1.6% |
| Affective Disorder |
1.5% |
| Fluid Replacement |
1.4% |
| Bipolar Ii Disorder |
1.2% |
| Hypothyroidism |
1.2% |
| Mental Disorder |
1.1% |
| Ill-defined Disorder |
1.0% |
| Insomnia |
0.9% |
|
| Therapeutic Agent Toxicity |
23.4% |
| Tremor |
15.6% |
| Toxicity To Various Agents |
8.7% |
| Vomiting |
8.2% |
| Renal Failure |
4.7% |
| Hyperparathyroidism |
4.6% |
| Renal Failure Chronic |
3.9% |
| Drug Ineffective |
3.7% |
| Weight Increased |
3.6% |
| Completed Suicide |
3.3% |
| Somnolence |
2.6% |
| Renal Impairment |
2.4% |
| Neuroleptic Malignant Syndrome |
2.3% |
| Suicide Attempt |
2.1% |
| White Blood Cell Count Increased |
2.1% |
| Death |
2.0% |
| Nephrogenic Diabetes Insipidus |
1.7% |
| Renal Failure Acute |
1.7% |
| Urinary Tract Infection |
1.7% |
| Thyroid Disorder |
1.6% |
|
| Secondary |
| Product Used For Unknown Indication |
25.6% |
| Bipolar Disorder |
18.2% |
| Drug Use For Unknown Indication |
16.3% |
| Depression |
8.8% |
| Bipolar I Disorder |
5.3% |
| Schizophrenia |
3.8% |
| Mania |
3.3% |
| Hypertension |
2.8% |
| Schizoaffective Disorder |
2.5% |
| Psychotic Disorder |
2.3% |
| Affective Disorder |
1.6% |
| Insomnia |
1.4% |
| Schizophrenia, Paranoid Type |
1.3% |
| Major Depression |
1.1% |
| Agitation |
1.1% |
| Ill-defined Disorder |
1.0% |
| Anxiety |
1.0% |
| Diabetes Mellitus |
0.8% |
| Depressive Symptom |
0.8% |
| Bipolar Ii Disorder |
0.8% |
|
| Tremor |
13.5% |
| Therapeutic Agent Toxicity |
11.5% |
| Completed Suicide |
9.8% |
| Weight Increased |
7.9% |
| Vomiting |
6.1% |
| Neuroleptic Malignant Syndrome |
6.0% |
| Suicide Attempt |
6.0% |
| Toxicity To Various Agents |
5.9% |
| Respiratory Arrest |
4.1% |
| Serotonin Syndrome |
3.9% |
| Renal Impairment |
3.7% |
| Weight Decreased |
3.1% |
| White Blood Cell Count Increased |
2.7% |
| Overdose |
2.5% |
| Drug Interaction |
2.4% |
| Suicidal Ideation |
2.4% |
| Death |
2.3% |
| Somnolence |
2.2% |
| Drug Ineffective |
2.0% |
| Mania |
2.0% |
|
| Concomitant |
| Bipolar Disorder |
24.2% |
| Product Used For Unknown Indication |
11.8% |
| Depression |
11.7% |
| Drug Use For Unknown Indication |
9.4% |
| Schizophrenia |
7.3% |
| Bipolar I Disorder |
4.9% |
| Schizoaffective Disorder |
4.1% |
| Anxiety |
4.0% |
| Insomnia |
3.1% |
| Sleep Disorder |
2.6% |
| Affective Disorder |
2.6% |
| Hypertension |
2.1% |
| Psychotic Disorder |
1.9% |
| Pain |
1.7% |
| Smoking Cessation Therapy |
1.7% |
| Schizophrenia, Paranoid Type |
1.5% |
| Mania |
1.4% |
| Prophylaxis |
1.3% |
| Rheumatoid Arthritis |
1.2% |
| Mood Swings |
1.2% |
|
| Weight Increased |
16.6% |
| Type 2 Diabetes Mellitus |
11.4% |
| Vomiting |
8.4% |
| Tremor |
6.5% |
| Weight Decreased |
5.6% |
| Suicide Attempt |
4.6% |
| Suicidal Ideation |
4.3% |
| Somnolence |
3.8% |
| Rash |
3.6% |
| White Blood Cell Count Increased |
3.6% |
| Pyrexia |
3.6% |
| Insomnia |
3.5% |
| White Blood Cell Count Decreased |
3.5% |
| Pancreatitis |
3.2% |
| Mania |
3.1% |
| Vision Blurred |
3.1% |
| Pulmonary Embolism |
3.0% |
| Tardive Dyskinesia |
3.0% |
| Diabetes Mellitus |
2.9% |
| Drug Ineffective |
2.6% |
|
| Interacting |
| Product Used For Unknown Indication |
27.4% |
| Bipolar Disorder |
20.0% |
| Drug Use For Unknown Indication |
11.7% |
| Depression |
8.5% |
| Mania |
5.2% |
| Bipolar I Disorder |
4.2% |
| Mental Disorder |
3.2% |
| Ill-defined Disorder |
2.6% |
| Smoking Cessation Therapy |
2.2% |
| Cardiac Disorder |
2.0% |
| Schizoaffective Disorder |
2.0% |
| Hypertension |
1.6% |
| Psychotic Disorder |
1.6% |
| Schizophrenia |
1.4% |
| Convulsion |
1.2% |
| Irritability |
1.2% |
| Essential Hypertension |
1.0% |
| Major Depression |
1.0% |
| Pain |
1.0% |
| Abnormal Behaviour |
0.8% |
|
| Drug Interaction |
21.1% |
| Tremor |
18.0% |
| Therapeutic Agent Toxicity |
7.8% |
| Toxicity To Various Agents |
7.8% |
| Encephalopathy |
4.7% |
| Erection Increased |
4.7% |
| Potentiating Drug Interaction |
3.9% |
| Psychomotor Hyperactivity |
3.1% |
| Serotonin Syndrome |
3.1% |
| White Blood Cell Count Increased |
3.1% |
| Antipsychotic Drug Level Increased |
2.3% |
| Dysarthria |
2.3% |
| Gait Disturbance |
2.3% |
| Hypothyroidism |
2.3% |
| Neuroleptic Malignant Syndrome |
2.3% |
| Priapism |
2.3% |
| Somnolence |
2.3% |
| Syncope |
2.3% |
| Thinking Abnormal |
2.3% |
| Diabetes Insipidus |
1.6% |
|
